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Photodynamic therapy (PDT) with Photofrin® is a promising treat-
ment modality for the management of a variety of solid neoplasms.
This modality was recently approved for the treatment of
oesophageal, lung, bladder, gastric and cervical cancers in various
countries (Dougherty et al, 1998). Clinical trials using PDT for the
treatment of cancers of other sites, including gastrointestinal tract,
are also being conducted (Dougherty et al, 1998; Kashtan et al,
1996). Although most of the regimens use PDT for palliative treat-
ment, it seems increasingly evident that this therapy might also be
useful in the treatment of a wide range of cancers, from early to
late stages (Reynolds, 1997).
PDT with Photofrin® involves the systemic administration of a
photosensitizer followed, after a time necessary for accumulation
of the sensitizer in the tumour, by the illumination of the tumour
area with visible light in the red or near-infrared spectral region
(Pass, 1993). There is an ample evidence that PDT, besides
eliciting direct cytotoxic effects towards tumour cells, involving
formation of reactive oxygen species (Henderson and Dougherty,
1992), also induces indirect anti-tumour effects resulting from
deprivation of oxygen and nutrients due to vaso-occlusion
(Ochsner, 1997). PDT is also capable of inducing apoptosis in
tumour cells (Granville et al, 1997; Ochsner, 1997; Ahmad et al,
1998). Moreover, PDT elicits non-specific and specific immune
responses against the tumour (Korbelik and Dougherty, 1999).
Endothelial cells seem to play a central role in these immune
responses. Besides constriction at the time of PDT exposure
(Fingar et al, 1992), endothelial cells facilitate platelet aggregation
and thrombus formation that eventually lead to blood flow stasis
(Ben-Hur et al, 1988; Foster et al, 1991; Fingar et al, 1997).
Simultaneously, intensive extravasation of leucocytes, especially
neutrophils and macrophages, into the tumour tissue is observed
(Krosl et al, 1995; Gollnick et al, 1997). These cells accumulate in
the tumour area as early as 5 min after PDT (Fingar et al, 1992),
where they may kill tumour cells directly (Faddy et al, 1990) or
indirectly through cooperation with lymphoid cells (Stoppacciaro
et al, 1993; Zilocchi et al, 1998).
Recent studies have demonstrated that the anti-tumour efficacy
of PDT can be improved by the administration of macrophage
activating factors such as granulocyte-macrophage colony-stimu-
lating factor (GM-SCF) (Krosl et al, 1996) or modified vitamin
D3-binding protein (Korbelik et al, 1997). Moreover, PDT efficacy
is attenuated in immune-deficient nude and severe combined
immune deficient (SCID) mice, implying the immune mechanisms
among the effectors of PDT (Korbelik et al, 1996). It has also been
observed that neutrophils are indispensable for successful PDT
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(de Vree et al, 1996a). Specifically, depletion of neutrophils in
tumour-bearing mice using polyclonal anti-granulocytes anti-
bodies (de Vree et al, 1996a), or blocking functions of cell adhe-
sion molecules engaged in the recruitment of these leucocytes in
tissues by anti-CD18 monoclonal antibody (de Vree et al, 1996b),
was found to decrease PDT-mediated anti-tumour effects. These
observations prompted us to investigate the extent to which inten-
sive G-CSF therapy, which results in increased production of
neutrophils, is capable of potentiating the anti-tumour efficacy of
PDT in mice.
MATERIALS AND METHODS
Mice
(C57BL/6 ´ DBA/2)F1 mice, hereafter called B6D2F1, and Balb/c
mice, 8–12 weeks of age, were used in the experiments. Breeding
pairs were obtained from the Inbred Mice Breeding Center of the
Institute of Immunology and Experimental Medicine (Wrocl /aw,
Poland), and from the Institute of Oncology, (Warsaw, Poland). All
experiments with animals were performed in accordance with the
guidelines approved by the Ethical Committee of the Medical
University of Warsaw.
Reagents
Photofrin®, was generous gift of QLT PhotoTherapeutics, Inc.
(Vancouver, BC, Canada). Recombinant human G-CSF
(Neupogen) was purchased from Hoffman-La Roche (Basel,
Switzerland). G-CSF was diluted with 0.1% bovine serum
albumin (BSA; Sigma, St. Louis, MO, USA) in phosphate-
buffered saline (PBS) for in vivo experiments.
Tumours
Colon-26 (C-26), a poorly differentiated and immunogenic colon
adenocarcinoma cells, and a non-immunogenic Lewis lung (3LL)
carcinoma cells were used. Cells were cultured in RPMI-1640
medium (Gibco-BRL, Paisley, UK) supplemented with 10% heat-
inactivated fetal calf serum (FCS), antibiotics, 2-mercaptoethanol
(50 mM) and L-glutamine (2 mM) (all from Gibco-BRL), hereafter
referred to as culture medium. For in vivo experiments exponen-
tially growing tumour cells were harvested, resuspended in PBS
medium to appropriate concentration of cells and injected (1 ´ 105
C-26 cells or 5 ´ 105 3LL cells in 20 ml PBS) into the footpad of
the right hind limb of experimental mice. Tumour cell viability
ranged between 96 and 97%.
Tumour treatment and monitoring
Tumour-bearing mice were treated with G-CSF intratumourally
(i.t.) starting from day 5 following inoculation of C-26 or 3LL
cells. G-CSF was given twice daily, every 12 h, for 5 consecutive
days, at a dose of 1 mg adjusted to 20 ml in 0.1% BSA-PBS. Mice
in control groups were injected with 20 ml 0.1% BSA-PBS i.t. in
the same regimen as the treated mice.
Photofrin® was administered intraperitoneally (i.p.) at a dose of
15 mg kg–1 24 h before illumination with 630-nm light (day 4 of
G-CSF administration, day 9 of the experiment). The light source
was a He-Ne ion laser (Amber, Warsaw, Poland). The light was
delivered on day 10 of the experiment using a fibreoptic light
delivery system. The power density at the illumination area, which
encompassed the tumour and 1–1.5 mm of the surrounding skin,
was approximately 80 mW cm–2 (40 mW laser output). The total
light dose delivered to the tumours was 150 J cm–2. During the
light treatment mice were anaesthetized with chloral hydrate
(3.6 mg kg–1) and restrained in a specially designed holder. Local
tumour growth was determined as described (Golab et al, 1998a)
by the formula:
Tumour volume (mm3) =
(longer diameter) ´ (shorter diameter)2
Relative tumour volume was calculated as follows:
Relative tumour volume =
[(tumor volume) ¸ (initial tumor volume)] ´ 100%.
Transient tumour oedema that developed after PDT was included
in the total volume of measured tumours.
Histopathology, immunohistochemistry and TUNEL
staining
The individual C-26 tumours were excised and snap-frozen 24 h
after PDT. Several cryostat sections, 10 mm thick, were made from
each tumour. Some sections were stained with haematoxylin and
eosin (H&E) routinely, the other sections underwent immunohis-
tochemical procedures and TUNEL staining. Two-step immuno-
histochemistry was performed, with a primary rat anti-mouse
neutrophil monoclonal antibody (clone RB6-8C5, Pharmingen,
San Diego, CA, USA) against Gr-1 epitope, and the secondary
being fluorescein isothiocyanate (FITC)-labelled goat F(ab´)2 anti-
rat IgG (H+L) (Southern Biotechnology Associates, Inc.,
Birmingham, AL, USA).
DNA fragmentation was detected by means of terminal
deoxynucleotide transferase based, in situ cell death detection kit
(TUNEL, Boehringer Mannheim, Germany). The procedure was
performed according to the manufacturer’s instructions.
Deoxynucleotide incorporated in DNA strand breaks was floures-
cein-labelled.
Analysis of peripheral blood cells
In the experiments in which the influence of Photofrin® and/or
G-CSF on haematopoiesis was studied, Balb/c mice were treated
in the same treatment regimen as in the above experiments. G-CSF
was given twice daily, every 12 h, for 5 consecutive days, at a dose
of 1 mg. Photofrin® was administered at a dose of 15 mg kg–1. Mice
in control groups were injected with 0.1% BSA-PBS and 5%
dextrose. Blood was collected from retroorbital sinus of anaes-
thetized mice 12 h after the last G-CSF dose and peripheral blood
cells were assessed using a Sysmex-820 cell counter (Sysmex,
Kyoto, Japan) adapted for the analysis of rodent cells.
In vitro colony assays
Spleen and bone marrow cells were collected 12 h after the last
G-CSF dose and the colony-forming units granulocyte–
macrophage (CFU-GM) and the colony-forming units granulo-
cyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM)
assays were performed as described previously (Golab
et al, 1998a).Potentiation of PDT by G-CSF 1487
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Luminol-enhanced chemiluminescence measurements
To evaluate the respiratory burst of oxygen-derived metabolites in
Balb/c mice treated with G-CSF and/or Photofrin®, the luminol-
enhanced chemiluminescence (ECL) was measured in whole
peripheral blood collected from retroorbital sinus 12 h after the
last G-CSF dose. Mice were treated with G-CSF and/or Photofrin®
as described above. Ten microlitres of peripheral blood, five times
diluted with Hanks balanced salt solution, was mixed with 200 ml
of luminol (1 ´ 10–5 M; Sigma). The vials were placed in the
measuring chamber of a liquid scintillator counter LKB Wallac
1409 with the chemiluminescence option (Pharmacia LKB, Turku,
Finland) for the measurement of spontaneous luminol-ECL. Then
20 ml of serum-opsonized zymosan (2 mg ml–1; Sigma) was added
to vials and the luminol-ECL of zymosan-activated cells was
measured using the same apparatus. The results were expressed as
counts per minute (cpm).
Statistical analysis
Data are presented as means ± standard error (s.e.). Differences in
tumour volume, chemiluminescence, numbers of bone marrow
and spleen colonies and peripheral blood leucocytes were analysed
for significance by Student’s t test. Additionally, data from in vivo
studies were analysed with the non-parametric Mann–Whitney
U-test (InstatTM, GraphPad Software, San Diego, CA, USA).
Kaplan–Meier plots were generated using days of animals death
(after inoculation of tumour cells) as a criterion, and survival time
of animal was analysed for significance by log-rank survival
analysis. Significance was defined as a two-sided P < 0.05.
RESULTS
Anti-tumour effects of PDT combined with G-CSF in
C-26 adenocarcinoma and 3LL carcinoma
As it has been reported in previous studies that the presence of
neutrophils contributes to the anti-tumour efficacy of PDT (de
Vree et al, 1996a), we evaluated the extent to which intensive
G-CSF therapy is capable of potentiating the anti-tumour efficacy
of PDT. G-CSF was administered i.t. for 5 consecutive days,
starting 5 days after inoculation of tumour cells. The dose and
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Figure 1 Anti-tumour effects of the combined treatment with Photofrin®-based PDT and G-CSF. G-CSF was administered i.t. at a dose of 1 mg, every 12 h, for
5 consecutive days, starting from day 5 after inoculation of tumour cells. Photofrin® was administered i.p. at a dose of 15 mg kg–1, 24 h before laser illumination
(150 J cm–2 on day 10 after inoculation of tumour cells). Measurements of tumour diameter started on day 7 after inoculation of tumour cells. (A) The influence
of the combined treatment on the growth of C-26 tumours in Balb/c mice (n = 8–9). (B) Kaplan–Meier plot of the survival of Balb/c mice bearing C-26 tumours.
(C) The influence of the combined treatment on the growth of 3LL tumours in B6D2F1 mice (n = 6–8). (D) Kaplan–Meier plot of the survival of B6D2F1 mice
bearing 3LL tumours. •P < 0.05 (Mann–Whitney U-test) in comparison with control and G-CSF-treated mice. *P < 0.05; **P < 0.01 (Mann–Whitney U-test) in
comparison with each of the remaining groups. #P < 0.05 (log-rank survival analysis) in comparison with controls and G-CSF treated mice); ##P < 0.01
(log-rank survival analysis) in comparison with each of the remaining groups. s – control; u u – G-CSF; n – PDT; Ñ – PDT + G-CSF1488 J Gol /a ˛b et al
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timing of G-CSF administration (1 mg, every 12 h) was chosen
based on our previous experiments demonstrating effective stimu-
lation of granulopoiesis in mice (Gol /a ˛b et al, 1998a). As shown in
Figure 1A, 1B, 1C and 1D, PDT produced potent anti-tumour
effects against both tumours that were manifested as a reduction of
tumour growth and a prolongation of mice survival time. Intensive
G-CSF treatment strongly potentiated these effects, further
reducing tumour growth. Mice treated with a combined (PDT and
G-CSF) regimen survived significantly longer than mice in all
other groups. Significantly, 33% of C-26-bearing mice (three of
nine) were cured of their tumours (no tumour for 150 days after
inoculation of C-26 cells). The cured mice (n = 3) rejected rechal-
lenge with even 10 times higher dose (1 ´  106) of C-26 cells
injected into the contralateral footpad on day 150, but did not
reject other tumour cells (Ha-ras-transformed 3T3 cells),
suggesting the development of specific immunity against the
treated tumour. Control mice (n = 6), injected at the time of rechal-
lenge, developed progressively growing tumours and died within
40 days after inoculation of tumour cells.
On H & E-stained sections, the C-26 tumours from both control
and G-CSF-treated mice were composed of solid malignant tissue,
with frequent mitotic figures (Figure 2 A and D). The architecture
of PDT-treated tumours was dramatically disturbed and neutro-
phils scattered between residual tumour cells were observed
(Figure 2G). However, there were also regions of undisturbed
tumour tissue after PDT only (not shown). In contrast, no such
regions of undisturbed tumour were observed on sections taken
from the tumours after combined treatment, and both tumour
Figure 2 Histologic analysis, indirect immunofluorescence and TUNEL staining of C-26 tumours. Tumours were obtained from controls (A–C), G-CSF (D–F),
PDT (G–I) and PDT + G-CSF (J–L) treated mice on day 11 of the experiment (24 h after laser illumination, where applicable). Haematoxylin and eosin staining
was performed routinely. On the sections of control (A) and G-CSF-treated (D) tumours there are densely packed neoplastic cells that form a uniform and solid
tumour mass. After PDT (G) the tumour architecture is disturbed dramatically, multiple foci of necrosis and/or apoptosis are found, with occasional granulocyte
infiltrations. Indirect immunofluorescence (anti-Gr-1) using monoclonal antibodies to detect neutrophils in the tumour specimens reveals single cells in the
control (B) and G-CSF-treated (E) specimens. The number of granulocytes in the PDT-treated tumours (H) is evidently greater and confined to focal areas,
especially under the epidermis. Importantly, the granulocyte infiltrations are most intensive and distributed throughout the tumour after the combined treatment
(K). The apoptotic DNA fragmentation was detected by means of terminal deoxynucleotide transferase based, in situ cell death detection kit (TUNEL). There are
only single apoptotic cells in tumours from controls (C) and G-CSF-treated (F) mice. The number of apoptotic cells is greater in tumours obtained from PDT-
treated mice (I). Tumour specimens obtained after combined treatment (L) contain cells that are predominantly either already apoptotic or in the early phases of
apoptosisPotentiation of PDT by G-CSF 1489
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destruction and neutrophil infiltrations were much more intensive
(Figure 2J).
Immunohistochemical staining of tumours taken from mice 24 h
after PDT confirmed infiltration of tumours by neutrophils (Figure
2H). Characteristically, the neutrophils were localized mainly in
superficial layers of tumours (close to the epidermis). However,
numerous neutrophils were also found deeper in the tumour. The
neutrophil infiltrations were substantially more intensive in
tumours treated with the combined therapy (Figure 2K). These
infiltrations were dense throughout the tumour.
In the tumours of mice treated with the combined regimen,
multiple sites with apoptotic cells were observed on histological
sections. To verify whether the observed cells were truly apoptotic,
a TUNEL staining was performed. Indeed, in the sections of
tumours treated with PDT, or PDT with G-CSF, numerous apop-
totic cells were present (Figure 2 I and L). Importantly, both the
neutrophil infiltration and the extent of apoptosis in tumours
treated with both PDT and G-CSF together were more intensive
than in tumours treated with PDT alone.
Effects of Photofrin® and G-CSF on myelopoiesis
It has previously been described that Photofrin® at doses used in
PDT accelerates myelopoietic recovery in irradiated mice and
increases responsiveness of myeloid cells to recombinant myeloid
growth factors (Hunt et al, 1995, 1998). Therefore, we decided to
examine the effects of co-administration of Photofrin® and G-CSF
(at doses used in the experiments with tumours) on the number of
peripheral blood leucocytes and colony forming capabilities of
bone marrow and spleen cells. Although Photofrin® did not signi-
ficantly influence the number of peripheral blood leucocytes in our
studies it slightly potentiated the effect of G-CSF (Table 1A).
To further investigate the effects of Photofrin® and G-CSF, we
examined the influence of these agents, administered either alone
or in combination, on the generation of spleen and bone marrow
CFU-GM and CFU-GEMM colonies (Table 1B). G-CSF adminis-
tered at doses used in the treatment of tumours increased the
number of bone marrow and spleen CFU-GM colonies.
Administration of a single bolus of Photofrin® slightly potentiated
Table 1 The influence of G-CSF and/or Photofrin® on haematopoiesis
(A) Changes in peripheral blood leucocyte counts in G-CSF and/or Photofrin®-treated mice
WBC Granulocytes Lymphocytes
Treatment group ´ 10–6 ml–1 ´ 10–6 ml–1 ´ 10–6 ml–1
Control 6.46 ± 0.52 1.16 ± 0.24 5.30 ± 0.45
Photofrin 6.09 ± 0.50 0.79 ± 0.13 5.30 ± 0.44
G-CSF 16.59 ± 1.81* 7.90 ± 1.10* 8.41 ± 0.92
Photofrin + G-CSF 20.35 ± 1.87* 11.38 ± 1.45* 8.97 ± 0.53*
(B) The influence of Photofrin® and/or G-CSF on CFU-GM and CFU-GEMM colony formation in the bone marrow and spleens. The numbers values refer to the
number of colonies per organ ´ 10–3
Bone marrow Spleen
Treatment group CFU-GEMM CFU-GM CFU-GEMM CFU-GM
Control 23.67 ± 1.99 78.20 ± 13.47 26.00 ± 3.52 69.40 ± 5.19
Photofrin 21.33 ± 2.44 109.20 ± 8.39 24.83 ± 1.97 93.50 ± 7.59*
G-CSF 24.67 ± 1.61 168.83 ± 6.06* 21.67 ± 1.41 579.29 ± 17.72*
Photofrin + G-CSF 23.00 ± 3.33 205.00 ± 20.67* 31.67 ± 3.12** 598.93 ± 48.84*
Balb/c mice (n = 6–8) were treated with G-CSF and/or Photofrin® in the same treatment schedule as in experiments in which antitumour activity was evaluated.
In controls 5% dextrose and 0.1% BSA-PBS were used. Results represent means ± s.e. *P < 0.05 versus controls; **P < 0.05 versus each of the remaining
groups. (Student’s t-test; two-tailed). The values refer to the number of colonies per organ ´ 10–3
Table 2 The influence of G-CSF and/or Photofrin® on peripheral blood neutrophil chemiluminescence
Clspont Clstym Ratio
Treatment group cpm cpm Clstym/Clspont
Control 3848 ± 459 6246 ± 893 1.65 ± 0.21
Photofrin 5186 ± 527 25807 ± 3546 4.92 ± 0.47*
G-CSF 5919 ± 1190 44491 ± 8006 9.29 ± 2.36*
Photofrin + G-CSF 9456 ± 1244 300716 ± 39344 38.27 ± 8.50**
Balbc mice (n = 8–10) were treated with G-CSF and/or Photofrin® in the same treatment schedule as in experiments in which anti-tumour activity was evaluated.
In controls 5% dextrose and 0.1% BSA-PBS were used. The values refer to counts per minute (cpm). The ratio of spontaneous to stimulated
chemiluminescence was counted in order to eliminate the differences in neutrophil counts between groups. Results represent means ± s.e. *P < 0.05 versus
controls; **P < 0.05 versus each of the remaining groups (Student’s t-test; two-tailed)1490 J Gol /a ˛b et al
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the influence of G-CSF on the number of bone marrow CFU-GM
colonies. Moreover, it significantly potentiated the influence of
G-CSF on the formation of CFU-GEMM colonies in the spleen.
Influence of Photofrin® and/or G-CSF administration on
luminol-ECL of peripheral blood granulocytes
We also decided to evaluate whether treatment with both agents
given alone or in combination affects one of the effector mecha-
nisms of mature granulocytes, namely the production of reactive
oxygen species. As expected, G-CSF treatment increased the
luminol-ECL of zymosan-activated peripheral blood granulocytes.
This effect was further significantly potentiated when mice were
given both agents simultaneously (Table 2).
DISCUSSION
de Vree et al (1996a) were the first to suggest that G-CSF could
potentiate anti-tumour efficacy of Photofrin®-based PDT.
However, in their study, G-CSF was administered at a very low
dose and for a short time only. As a result, the retardation of
tumour growth was observed on 1 day only in rats treated with
Photofrin®-based PDT and G-CSF as compared with PDT-treated
animals. Since G-CSF is relatively well tolerated, we decided to
administer it at high doses that ensure a strong and consistent
stimulation of myelopoiesis (Gola ¸b et al, 1998a).
The results of the present report indicate that treatment with
high doses of G-CSF strongly potentiates the anti-tumour effects
of PDT. This combined therapy was effective not only in the
reduction of tumour growth, but also in the prolonging of mice
survival time (Figure 1). Moreover, in C-26 tumour model a
combined treatment produced almost 33% cures, an effect not
observed in animals of any other treatment groups in our experi-
ments (Figure 1 B and D).
Treatment of tumours with PDT elicits a strong and localized
inflammatory response as lymphocytes, granulocytes,
macrophages and mast cells are found to rapidly infiltrate PDT-
treated tumours (Krosl et al, 1995; Gollnick et al, 1997). A number
of cytokines are produced within tumours after PDT. Interleukin
(IL)-1b, IL-2 and tumour necrosis factor (TNF) are present in the
urine of bladder cancer patients treated with Photofrin®-based
PDT (Nseyo et al, 1990). Fragments of PDT-killed tumour cells,
inflammatory cytokines and infiltrating leucocytes, capable of
engulfing and presenting tumour antigens to T lymphocytes, might
create a unique environment for promoting cell-mediated immu-
nity. Administration of G-CSF, by increasing the number and acti-
vation status of granulocytes, possibly extends the repertoire of
antigen-presenting cells, further facilitating the development of
specific anti-tumour immune response (Stoppacciaro et al, 1993).
Indeed, it has been reported that activated granulocytes infiltrating
tumours are capable of producing IL-1a, IL-1b, IL-8 and TNF,
and of cooperating with CD8+ cytotoxic T lymphocytes in the
induction of effective anti-tumour immunity (Stoppacciaro et al,
1993; Zilocchi et al, 1998). It has also been previously observed
that PDT generates tumour-specific T lymphocytes that can be
recovered from distant lymphoid organs, such as lymph nodes or
spleen, even after protracted times after light treatment (Korbelik,
1996). Moreover, the effectiveness of PDT in either SCID or nude
mice is greatly attenuated as compared with wild-type mice.
Adoptive T-cells or bone marrow transfer into nude or SCID mice
were effective in delaying the recurrence of PDT-treated tumours
(Korbelik et al, 1996).
Although, it cannot be excluded that the observed anti-tumour
effects of the combined treatment might result from the G-CSF-
induced changes in the level and distribution of Photofrin®, the
effectiveness of the combined PDT and G-CSF treatment seems to
result from the increased tumour infiltration by neutrophils. G-
CSF and Photofrin® are capable of synergistically stimulating the
activation of these cells (increased chemiluminescence; Table 2).
By inducing increased vascular permeability PDT facilitates
tumour infiltration by activated neutrophils that could kill attenu-
ated tumour cells. The striking increase in the number of apoptotic
cells in tumours treated with the combination therapy might be a
result of increased death of both tumour cells and activated
neutrophils that so massively infiltrate the neoplatic tissue (Figure
2L). Apoptotic tumour cells might then be phagocytosed by
dendritic cells enabling them to process and present tumour-
derived peptides to T-cells, thus inducing the development of anti-
tumour immune response (Albert et al, 1998). This response seems
to be long-lasting as mice cured of their tumours were able to
reject second rechallenge with tumour cells even after 150 days
after initiation of the experiment. Moreover, it seems that the
immune response is specific, since cured mice were not able to
reject another, syngeneic tumour.
Combined PDT and G-CSF treatment could have additional
benefits for cancer patients that are also frequently treated with
myelosuppressive regimens including radio- and chemotherapy.
G-CSF can decrease the duration of neutropenia and the risk of
infections in both neutropenic and non-neutropenic patients under-
going chemotherapy (Welte et al, 1996).
Interestingly, Photofrin® alone demonstrates a number of
biologic effects. It promotes haematopoietic activity within bone
marrow and spleens of normal mice partly through the increased
responsiveness to recombinant myeloid and erythroid growth
factors (Hunt et al, 1995, 1998). In our studies, we observed
increased activation of granulocytes obtained from mice treated
with both Photofrin® and G-CSF. These cells revealed an enhanced
responsiveness to zymosan, a strong activator of reactive oxygen
species production. These effects might be relevant not only in the
strengthened anti-tumour activity of granulocytes but also in the
enhanced protection of tumour patients against febrile infections.
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